Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma

PURPOSE: We determine the maximum-tolerated dose (MTD), pharmacokinetics, safety, and preliminary efficacy of SAR3419, an antibody-drug conjugate targeting CD19, in a first-in-man phase I clinical trial in patients with relapsed lymphoma. PATIENTS AND METHODS: Patients with relapsed CD19+ B-cell lym...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Younes, Anas, Kim, Stella, Romaguera, Jorge, Copeland, Amanda, Farial, Silvana de Castro, Kwak, Larry W., Fayad, Luis, Hagemeister, Frederick, Fanale, Michelle, Neelapu, Sattva, Lambert, John M., Morariu-Zamfir, Rodica, Payrard, Sandrine, Gordon, Leo I.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2012
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5950497/
https://ncbi.nlm.nih.gov/pubmed/22753910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.39.4403
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars